Hence, we hope to investigate whether CTLA-4 mediates T cell exhaustion and make CTLA-4 a novel therapeutic target for reversing the immunosuppressive effect in AE patients. This evidence concerns the gene CTLA4 and acrodermatitis enteropathica.